Racial Disparities in Systemic Sclerosis: Short- and Long-Term Outcomes Among African American Participants of SLS I and II.
Racial Disparities in Systemic Sclerosis: Short- and Long-Term Outcomes Among African American Participants of SLS I and II.
复制标题
DOI：
10.1002/acr2.11206
复制
发表时间：
2021-01
影响因子：
3.4
通讯作者：
Tashkin DP
中科院分区：
文献类型：
--
作者：
Volkmann ER;Steen V;Li N;Roth MD;Clements PJ;Furst DE;Assassi S;Khanna D;Kim GJ;Goldin J;Elashoff RM;Tashkin DP
评价硬皮病肺研究（SLS）I和II的非裔美国人（AA）受试者的短期和长期结局。SLS I将158例系统性硬化症-间质性肺病（SSc-ILD）受试者随机分配至1年口服环磷酰胺（CYC）与安慰剂组。SLS II将142例SSc‐ILD受试者随机分配至1年口服CYC，随后1年安慰剂与2年霉酚酸酯（MMF）。联合模型比较了AA和非AA之间的用力肺活量（FVC）和一氧化碳弥散量（DLCO），考克斯比例风险模型评估了长期发病率和死亡率结局。在SLS I中，两个治疗组中AA和非AA之间的FVC或DLCO病程无差异。在SLS II中，CYC组中AA的FVC病程较非AA改善;在MMF组中，FVC病程无差异。两组的DLCO病程无差异。SLS I中AA和非AA的至死亡和呼吸衰竭时间相似。SLS II中，与非AA相比，AA的生存率和至呼吸衰竭时间有改善的趋势。在考克斯模型中，AA人种与SLS I或II的死亡率无关。来自两项随机对照试验的数据表明，与非AA患者相比，患有SSc‐ILD的AA患者的发病率和死亡率结局相似。这些发现与先前观察性研究中描述的种族差异形成对比，需要进一步调查。
To evaluate short‐ and long‐term outcomes of African American (AA) participants of Scleroderma Lung Studies (SLS) I and II. SLS I randomized 158 participants with systemic sclerosis‐interstitial lung disease (SSc‐ILD) to 1 year of oral cyclophosphamide (CYC) versus placebo. SLS II randomized 142 participants with SSc‐ILD to 1 year of oral CYC followed by 1 year of placebo versus 2 years of mycophenolate (MMF). Joint models compared the course of forced vital capacity (FVC) and diffusing capacity for carbon monoxide (DLCO) between AA and non‐AA, and Cox proportional hazard models assessed long‐term morbidity and mortality outcomes. In SLS I, there was no difference in the course of the FVC or DLCO between AA and non‐AA in either treatment arm. In SLS II, AA had an improved course of the FVC compared with non‐AA in the CYC arm; in the MMF arm, there was no difference in FVC course. There was no difference in DLCO course in either arm. Time to death and respiratory failure were similar for AA and non‐AA in SLS I. There was a trend for improved survival and time to respiratory failure in AA compared with non‐AA in SLS II. AA race was not independently associated with mortality in the SLS I or II in the Cox models. Data from two randomized controlled trials demonstrated that AA patients with SSc‐ILD have similar morbidity and mortality outcomes compared with non‐AA patients. These findings contrast with the racial disparities described in prior observational studies and warrant further investigation.
登录
查看更多内容
影响因子：
27.4
作者：
Volkmann ER;Tashkin DP;Sim M;Li N;Goldmuntz E;Keyes-Elstein L;Pinckney A;Furst DE;Clements PJ;Khanna D;Steen V;Schraufnagel DE;Arami S;Hsu V;Roth MD;Elashoff RM;Sullivan KM;SLS I and SLS II study groups
通讯作者：
SLS I and SLS II study groups
影响因子：
158.5
作者：
Tashkin, Donald P.;Elashoff, Robert;Metersky, Mark
通讯作者：
Metersky, Mark
影响因子：
158.5
作者：
Distler, Oliver;Highland, Kristin B.;Maher, Toby M.
通讯作者：
Maher, Toby M.
影响因子：
--
作者：
Steen, VD;Oddis, CV;Medsger, TA
通讯作者：
Medsger, TA
影响因子：
1.6
作者：
Morgan, Nadia D.;Shah, Ami A.;Boin, Francesco
通讯作者：
Boin, Francesco